GlaxoSmithKline's quarterly earnings received a lukewarm reception today as shares in the drugs giant slipped 3%.
This was despite a better than expected rise of 13% in earnings thanks to strong sales of vaccines and consumer products.
The company's new chief executive, Andrew Witty, also laid out plans for a broader business with a simplified structure.
The share price fall - to £11.91 - put the stock in the top 10 fallers in the FTSE 100.
Pharma counterpart AstraZeneca was also a top-ten loser, down by 1.5% to £22.89.
Otherwise, most of the bluechip index's major fallers were miners and oil groups because of declines in the price of metals and oil.
Iron ore producer Ferrexpo fell 3% to 267p, making it the FTSE 100's biggest faller.
Platinum specialist Lonmin was down 2% to £26, as the excitement around yesterday's talk of a bid from Xstrata died down.
Brewing giant SAB Miller lost 2% to slide to £10.92 as Goldman Sachs put the stock on its "pan-Europe conviction sell list".
